Travere Therapeutics (TVTX) net assets (shareholders' equity)

Net assets · fiscal 2025
$114.83M

Travere Therapeutics (TVTX) had net assets of $114.83M at the end of fiscal 2025 (December 31, 2025). That is 94.4% higher than the $59.08M of fiscal 2024. Figures as of 19 Nov 2026, 03:35 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$114.83M
Change on fiscal 2024
+94.4%
Growth, 5 years
−11.5% a year
Growth, 10 years
−9.2% a year
Highest on record
$318.25Mfiscal 2018
Lowest on record
-$37.25Mfiscal 2014
Fiscal years on record
162011–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Travere Therapeutics net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets shrank at a compound 11.5% a year; over ten years the rate was −9.2% a year. Across the 16 fiscal years on record (2011–2025), the highest was $318.25M in fiscal 2018 and the lowest -$37.25M in fiscal 2014.

History · 16 fiscal years

Net assets by fiscal year

Travere Therapeutics net assets (shareholders' equity), year by year

Travere Therapeutics (TVTX) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$114.83M 94.4% up
2024$59.08M 70.6% down
2023$200.81M 368.6% up
2022$42.85M 85.8% down
2021$302.11M 43.0% up
2020$211.21M 4.5% down
2019$221.20M 30.5% down
2018$318.25M 8.6% up
2017$293.13M 4.8% down
2016$307.77M 2.6% up
2015$299.97M—
2014-$37.25M—
2013-$19.67M—
2012-$3.41M—
2012-$63.08K—
2011-$60.26K—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Travere Therapeutics and comparable companies
CompanyNet assetsFiscal year
MiniMed Group MMED$3.61B2026
Adaptive Biotechnologies ADPT$218.79M2025
Heartflow HTFL$300.65M2025
CRISPR Therapeutics CRSP$1.92B2025
Travere Therapeutics TVTX$114.83M2025
Option Care Health OPCH$1.33B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TVTX

Travere Therapeutics, figure by figure

Travere Therapeutics (TVTX) overview: price, valuation and scorecardAll health care companies by market value

Travere Therapeutics net assets (shareholders' equity): questions and answers

What are Travere Therapeutics's net assets?

Travere Therapeutics (TVTX) had net assets of $114.83M at the end of fiscal 2025 (December 31, 2025). That is 94.4% higher than the $59.08M of fiscal 2024.

What is the growth rate of Travere Therapeutics's net assets?

Over the five fiscal years to 2025 net assets shrank at a compound 11.5% a year; over ten years the rate was −9.2% a year.

What are the highest and lowest net assets figures on record for Travere Therapeutics?

Across the 16 fiscal years on record (2011–2025), the highest was $318.25M in fiscal 2018 and the lowest -$37.25M in fiscal 2014.

How is Travere Therapeutics's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Travere Therapeutics it is on record here for 16 fiscal years, 2011 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Travere Therapeutics (TVTX) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/TVTX/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.